{
  "id": "autoimmune-dementia",
  "title": "Autoimmune Dementia / Encephalopathy",
  "version": "1.0",
  "icd10": [
    "** G04.81 (Other autoimmune encephalitis)",
    "G31.09 (Other frontotemporal dementia)",
    "G04.90 (Encephalitis and encephalomyelitis",
    "unspecified)",
    "R41.3 (Other amnesia)",
    "G13.1 (Other systemic atrophy primarily affecting CNS in neoplastic disease — paraneoplastic limbic encephalitis)"
  ],
  "scope": "** Evaluation and management of autoimmune-mediated cognitive decline and encephalopathy. This is a \"must-not-miss\" diagnosis — autoimmune dementia is one of the few truly treatable and potentially reversible causes of dementia and rapidly progressive cognitive decline. Covers antibody-mediated encephalitis (NMDAR, LGI1, CASPR2, AMPAR, GABA-B, DPPX), paraneoplastic limbic encephalitis, and seronegative autoimmune encephalopathy. Includes rapid diagnostic workup, empiric immunotherapy, cancer screening, and long-term maintenance. Applies to all clinical settings.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "— Core Labs (Order for All Patients)": [
        {
          "item": "CBC with differential",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Infection, lymphoma, paraneoplastic hematologic markers"
        },
        {
          "item": "CMP (comprehensive metabolic panel)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Hepatic, renal, electrolyte, glucose — exclude metabolic encephalopathy"
        },
        {
          "item": "TSH, free T4",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "Thyroid disease; also needed for SREAT workup"
        },
        {
          "item": "Anti-TPO antibodies",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "SREAT/Hashimoto encephalopathy — elevated in ~85% of cases; but also elevated in ~10% of general population (low specificity)"
        },
        {
          "item": "Anti-thyroglobulin antibodies",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "Second thyroid antibody for SREAT — increases sensitivity"
        },
        {
          "item": "ESR",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "Inflammatory marker; elevated in vasculitis, systemic autoimmune, infection"
        },
        {
          "item": "CRP",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "Inflammatory marker"
        },
        {
          "item": "Vitamin B12",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "Exclude B12 deficiency — treatable cause of cognitive decline"
        },
        {
          "item": "RPR/VDRL",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "Neurosyphilis — must rule out in RPD workup"
        },
        {
          "item": "HIV 1/2",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "rationale": "HIV-associated neurocognitive disorder"
        },
        {
          "item": "Urinalysis",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT",
          "rationale": "Exclude UTI (delirium), proteinuria (systemic autoimmune)"
        }
      ],
      "— Extended Labs — Autoimmune and Paraneoplastic Panel": [
        {
          "item": "**Serum autoimmune encephalitis panel**",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "URGENT",
          "ICU": "URGENT",
          "rationale": "**Critical** — NMDA-R Ab, LGI1 Ab, CASPR2 Ab, AMPA-R Ab, GABA-B Ab, DPPX Ab; send to reference lab (Mayo, Quest Autoimmune); results take 1-3 weeks — **do NOT wait for results to start empiric immunotherapy if clinical suspicion is high**"
        },
        {
          "item": "**CSF autoimmune encephalitis panel**",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT",
          "rationale": "**Essential — more sensitive than serum for NMDAR antibodies** (serum can be negative with positive CSF in up to 14%); CSF should be sent simultaneously with serum; also include GABA-A, IgLON5"
        },
        {
          "item": "**CSF cell count, protein, glucose**",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT",
          "rationale": "Lymphocytic pleocytosis (WBC 5-100, predominantly lymphocytes) supports autoimmune encephalitis; elevated protein common; glucose usually normal (vs infectious meningitis)"
        },
        {
          "item": "**CSF oligoclonal bands and IgG index**",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT",
          "rationale": "Intrathecal IgG synthesis — supports CNS autoimmune process; also evaluate for MS"
        },
        {
          "item": "**CSF cytology**",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT",
          "rationale": "Lymphomatous meningitis, carcinomatous meningitis — on RPD differential"
        },
        {
          "item": "**CSF 14-3-3, RT-QuIC, tau**",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT",
          "rationale": "**Prion disease exclusion** — 14-3-3 sensitivity ~85% for CJD; RT-QuIC sensitivity >90%, specificity >99%; total tau >1150 pg/mL highly suggestive of CJD"
        },
        {
          "item": "**Paraneoplastic antibody panel (serum)**",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "URGENT",
          "ICU": "URGENT",
          "rationale": "ANNA-1 (Hu), ANNA-2, PCA-1 (Yo), PCA-2, PCA-Tr (DNER), CV2/CRMP5, Ma2/Ta, amphiphysin, GAD65 (high titer >20 nmol/L)"
        },
        {
          "item": "ANA",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Systemic lupus, Sjogren's — CNS involvement"
        },
        {
          "item": "dsDNA, SSA/SSB, complement C3/C4",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Lupus cerebritis, neurosarcoidosis, Sjogren's"
        },
        {
          "item": "ANCA (c-ANCA, p-ANCA)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "CNS vasculitis"
        },
        {
          "item": "ACE level",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Neurosarcoidosis"
        },
        {
          "item": "Quantitative immunoglobulins",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "IgG subclass deficiency; immunodeficiency evaluation"
        }
      ],
      "— Rare/Specialized Labs": [
        {
          "item": "CSF flow cytometry",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE",
          "rationale": "CNS lymphoma — in RPD differential"
        },
        {
          "item": "CSF beta-amyloid and phospho-tau",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "AD biomarkers — low Aβ42/high p-tau suggests neurodegenerative, not autoimmune; useful to differentiate"
        },
        {
          "item": "CSF VDRL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE",
          "rationale": "Neurosyphilis confirmation"
        },
        {
          "item": "Serum/CSF Whipple PCR",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "EXT",
          "rationale": "Whipple disease — rare but treatable cause of RPD"
        },
        {
          "item": "Heavy metals (lead, mercury, arsenic)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Toxic encephalopathy — if exposure history"
        },
        {
          "item": "Copper, ceruloplasmin",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Wilson disease (if age <50)"
        },
        {
          "item": "IgLON5 antibody (CSF)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "ROUTINE",
          "rationale": "IgLON5 disease — sleep disorder, cognitive decline, brainstem dysfunction; unique tauopathy"
        },
        {
          "item": "GFAP antibody (CSF/serum)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "ROUTINE",
          "rationale": "Autoimmune GFAP astrocytopathy — meningoencephalitis, often with perivascular pattern on MRI"
        }
      ]
    },
    "Imaging & Studies": {
      "— Essential Imaging": [
        {
          "item": "MRI brain with/without contrast (thin-cut temporal, FLAIR, DWI, T2, post-gad)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "URGENT",
          "ICU": "STAT",
          "rationale": "**First-line and most important imaging** — T2/FLAIR hyperintensity in mesial temporal lobes (hippocampus, amygdala) is classic for limbic encephalitis; DWI cortical ribboning suggests CJD; enhancement patterns vary by antibody type; may be normal in up to 30% of autoimmune encephalitis"
        },
        {
          "item": "EEG (routine or continuous)",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Seizures (often subclinical), extreme delta brush (pathognomonic for anti-NMDAR encephalitis), periodic discharges (CJD), diffuse slowing (encephalopathy); continuous EEG in ICU patients"
        },
        {
          "item": "CT head without contrast",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT",
          "rationale": "Rapid screening in ED to exclude mass, hemorrhage, hydrocephalus; MRI is ultimately needed"
        },
        {
          "item": "Chest X-ray",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT",
          "rationale": "Malignancy screening (lung cancer — Hu, CRMP5); infection"
        }
      ],
      "— Extended Imaging — Cancer Screening": [
        {
          "item": "CT chest/abdomen/pelvis with contrast",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "URGENT",
          "ICU": "URGENT",
          "rationale": "Comprehensive cancer screening — lung (SCLC → Hu, CRMP5, AMPAR), ovarian teratoma (NMDAR), thymoma (CASPR2, LGI1), lymphoma, renal"
        },
        {
          "item": "Pelvic/transvaginal ultrasound (females)",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "URGENT",
          "ICU": "URGENT",
          "rationale": "Ovarian teratoma screening — **mandatory in anti-NMDAR encephalitis** in women; teratoma removal is therapeutic; may require MRI pelvis if US inconclusive"
        },
        {
          "item": "Testicular ultrasound (males <50)",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "URGENT",
          "ICU": "URGENT",
          "rationale": "Testicular tumor screening in young males with anti-NMDAR or Ma2 antibodies"
        },
        {
          "item": "PET/CT (whole body)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Most sensitive for occult malignancy when CT is negative; particularly useful for paraneoplastic antibodies with intracellular targets (Hu, Yo, Ma2)"
        },
        {
          "item": "MRI pelvis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "If ovarian teratoma suspected but US inconclusive"
        },
        {
          "item": "Mammography / breast MRI",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "If amphiphysin antibody positive — associated with breast cancer"
        }
      ],
      "— Rare/Specialized Studies": [
        {
          "item": "FDG-PET brain",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Hypermetabolism in medial temporal lobes (limbic encephalitis) vs hypometabolism (neurodegenerative); can be positive when MRI is normal"
        },
        {
          "item": "Brain biopsy",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "EXT",
          "rationale": "Last resort — only if all other investigations negative and progressive decline; rule out CNS vasculitis, lymphoma, CJD; high morbidity; should target area of abnormality on MRI"
        },
        {
          "item": "Conventional cerebral angiography",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "EXT",
          "rationale": "If primary CNS vasculitis suspected (beading pattern); can be normal in small vessel vasculitis"
        },
        {
          "item": "Neuropsychological testing",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Document cognitive profile, track treatment response, differentiate from neurodegenerative patterns; LGI1 typically limbic (amnesia); NMDAR often frontal-subcortical"
        }
      ]
    },
    "Treatment": {
      "— Acute / First-Line Immunotherapy": [
        {
          "item": "Methylprednisolone IV (pulse)",
          "route": "IV",
          "indication": "First-line acute immunotherapy; often combined with IVIG or PLEX",
          "dosing": {
            "doseOptions": [
              {
                "text": "1000 mg",
                "orderSentence": "Methylprednisolone IV (pulse) 1000 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "infuse over 1 hour; premedicate with famotidine",
            "orderSentence": "Methylprednisolone IV (pulse) 1000 mg IV"
          },
          "contraindications": "Avoid if CJD is the primary concern (steroids do not help and delay diagnosis)",
          "monitoring": "Glucose (hyperglycemia), blood pressure, insomnia, psychiatric side effects",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "IVIG (intravenous immunoglobulin)",
          "route": "IV",
          "indication": "First-line acute immunotherapy; often combined with steroids; preferred over PLEX in many centers due to ease of administration",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.4 g/kg/day",
                "orderSentence": "IVIG (intravenous immunoglobulin) 0.4 g/kg/day IV"
              }
            ],
            "route": "IV",
            "instructions": "infuse per protocol (total 2 g/kg divided over 5 days); premedicate with acetaminophen, diphenhydramine",
            "orderSentence": "IVIG (intravenous immunoglobulin) 0.4 g/kg/day IV"
          },
          "contraindications": "IgA deficiency (anaphylaxis risk — check IgA level before first dose); thrombosis risk",
          "monitoring": "Infusion reactions, IgA level before first dose",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Plasma exchange (PLEX)",
          "route": "Extracorporeal",
          "indication": "First-line alternative to IVIG; preferred in severe/ICU cases; more rapid antibody clearance",
          "dosing": {
            "doseOptions": [
              {
                "text": "5-7 sessions",
                "orderSentence": "Plasma exchange (PLEX) 5-7 sessions extracorporeal"
              }
            ],
            "route": "extracorporeal",
            "instructions": "total 1-1.5 plasma volumes per session; requires central venous access",
            "orderSentence": "Plasma exchange (PLEX) 5-7 sessions extracorporeal"
          },
          "contraindications": "-",
          "monitoring": "Hypotension, electrolyte imbalance, coagulopathy, line infection",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "— Second-Line Immunotherapy (If First-Line Fails)": [
        {
          "item": "Rituximab IV",
          "route": "IV",
          "indication": "First-choice second-line agent; anti-CD20 B-cell depletion; effective in NMDAR, LGI1, CASPR2, and many other antibody-mediated encephalitides",
          "dosing": {
            "doseOptions": [
              {
                "text": "375 mg/m²",
                "orderSentence": "Rituximab IV 375 mg/m² IV"
              }
            ],
            "route": "IV",
            "instructions": "or 1000 mg IV x 2 doses 2 weeks apart; pre-treat with methylprednisolone 100 mg IV, acetaminophen, diphenhydramine",
            "orderSentence": "Rituximab IV 375 mg/m² IV"
          },
          "contraindications": "Hepatitis B (reactivation risk — screen before starting); PML risk (rare)",
          "monitoring": "Onset of action 2-4 weeks; hepatitis B serology before starting",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Cyclophosphamide IV",
          "route": "IV",
          "indication": "Second-choice second-line; used with rituximab in severe refractory anti-NMDAR encephalitis",
          "dosing": {
            "doseOptions": [
              {
                "text": "750-1000 mg/m²",
                "orderSentence": "Cyclophosphamide IV 750-1000 mg/m² IV"
              }
            ],
            "route": "IV",
            "instructions": "with MESNA and aggressive hydration",
            "orderSentence": "Cyclophosphamide IV 750-1000 mg/m² IV"
          },
          "contraindications": "Significant toxicity: hemorrhagic cystitis, infertility, secondary malignancy",
          "monitoring": "CBC weekly during treatment; myelosuppression monitoring",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        }
      ],
      "— Maintenance Immunotherapy (Relapse Prevention)": [
        {
          "item": "Prednisone PO (taper)",
          "route": "PO",
          "indication": "Oral steroid bridge after IV pulse; long-term maintenance in relapse-prone patients",
          "dosing": {
            "doseOptions": [
              {
                "text": "60 mg",
                "orderSentence": "Prednisone PO (taper) 60 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "taper by 10 mg/week to 20 mg, then 5 mg/week to off; or maintain 10-20 mg daily long-term if relapse-prone",
            "orderSentence": "Prednisone PO (taper) 60 mg PO"
          },
          "contraindications": "-",
          "monitoring": "Cushingoid effects, osteoporosis (start calcium + vitamin D), hyperglycemia, cataracts",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Mycophenolate mofetil PO",
          "route": "PO",
          "indication": "Steroid-sparing maintenance; commonly used for LGI1, CASPR2, autoimmune encephalitis relapse prevention",
          "dosing": {
            "doseOptions": [
              {
                "text": "500-1000 mg",
                "orderSentence": "Mycophenolate mofetil PO 500-1000 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "start 500 mg BID, increase to 1000 mg BID over 2-4 weeks",
            "orderSentence": "Mycophenolate mofetil PO 500-1000 mg PO"
          },
          "contraindications": "Teratogenic — pregnancy prevention mandatory",
          "monitoring": "CBC every 2-4 weeks initially",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Azathioprine PO",
          "route": "PO",
          "indication": "Alternative steroid-sparing maintenance agent",
          "dosing": {
            "doseOptions": [
              {
                "text": "1-3 mg/kg/day",
                "orderSentence": "Azathioprine PO 1-3 mg/kg/day PO"
              }
            ],
            "route": "PO",
            "instructions": "start 50 mg daily, titrate up over 4-6 weeks",
            "orderSentence": "Azathioprine PO 1-3 mg/kg/day PO"
          },
          "contraindications": "Poor TPMT metabolizers at risk for severe myelosuppression (check TPMT genotype before starting)",
          "monitoring": "CBC, LFTs; onset of action 3-6 months",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rituximab IV (maintenance)",
          "route": "IV",
          "indication": "Long-term B-cell depletion for relapsing autoimmune encephalitis",
          "dosing": {
            "doseOptions": [
              {
                "text": "500-1000 mg",
                "orderSentence": "Rituximab IV (maintenance) 500-1000 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "or guided by CD19/CD20 B-cell reconstitution",
            "orderSentence": "Rituximab IV (maintenance) 500-1000 mg IV"
          },
          "contraindications": "Infection risk; hypogammaglobulinemia with repeated cycles",
          "monitoring": "Immunoglobulins (hypogammaglobulinemia), CD19/CD20 B-cell count",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "— Tumor Treatment (Paraneoplastic Cases)": [
        {
          "item": "Tumor resection/treatment",
          "route": "-",
          "indication": "Essential in all paraneoplastic cases; neurologic improvement is unlikely without tumor treatment",
          "dosing": {
            "instructions": "Ovarian teratoma removal (anti-NMDAR); SCLC treatment (chemo/radiation); thymectomy for thymoma-associated cases",
            "orderSentence": "Tumor resection/treatment - - - see dosing"
          },
          "contraindications": "-",
          "monitoring": "Post-operative neurologic status; antibody titers post-resection",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "URGENT",
          "ICU": "URGENT"
        },
        {
          "item": "Repeat cancer screening",
          "route": "-",
          "indication": "Paraneoplastic antibodies confirmed but initial screening negative; occult tumors may emerge later",
          "dosing": {
            "instructions": "Repeat imaging at 3-6 month intervals for up to 5 years",
            "orderSentence": "Repeat cancer screening - - - see dosing"
          },
          "contraindications": "-",
          "monitoring": "Serial imaging (CT, PET/CT) per cancer surveillance schedule",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "— Seizure Management": [
        {
          "item": "Levetiracetam",
          "route": "PO/IV",
          "indication": "First-line ASM for autoimmune encephalitis seizures; minimal drug interactions",
          "dosing": {
            "doseOptions": [
              {
                "text": "500-1500 mg",
                "orderSentence": "Levetiracetam 500-1500 mg PO/IV"
              }
            ],
            "route": "PO/IV",
            "instructions": "start 500 mg BID, titrate to effect",
            "orderSentence": "Levetiracetam 500-1500 mg PO/IV"
          },
          "contraindications": "May exacerbate psychiatric symptoms (irritability)",
          "monitoring": "Psychiatric side effects, renal function",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Lacosamide",
          "route": "PO/IV",
          "indication": "Well-tolerated alternative ASM; good IV formulation",
          "dosing": {
            "doseOptions": [
              {
                "text": "50-200 mg",
                "orderSentence": "Lacosamide 50-200 mg PO/IV"
              }
            ],
            "route": "PO/IV",
            "instructions": "start 50 mg BID, titrate by 50 mg/week",
            "orderSentence": "Lacosamide 50-200 mg PO/IV"
          },
          "contraindications": "-",
          "monitoring": "PR interval",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Brivaracetam",
          "route": "PO/IV",
          "indication": "Alternative to levetiracetam with potentially fewer psychiatric side effects",
          "dosing": {
            "doseOptions": [
              {
                "text": "25-100 mg",
                "orderSentence": "Brivaracetam 25-100 mg PO/IV"
              }
            ],
            "route": "PO/IV",
            "instructions": "25-100 mg :: PO/IV :: BID",
            "orderSentence": "Brivaracetam 25-100 mg PO/IV"
          },
          "contraindications": "-",
          "monitoring": "-",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        }
      ],
      "— Symptomatic and Supportive Treatment": [
        {
          "item": "Quetiapine",
          "route": "PO",
          "indication": "Psychiatric symptoms (agitation, psychosis); common in NMDAR encephalitis; low-dose atypical antipsychotics preferred",
          "dosing": {
            "doseOptions": [
              {
                "text": "25-100 mg",
                "orderSentence": "Quetiapine 25-100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "25-100 mg :: PO :: qhs",
            "orderSentence": "Quetiapine 25-100 mg PO"
          },
          "contraindications": "Avoid high doses (may lower seizure threshold)",
          "monitoring": "Sedation, metabolic effects",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Olanzapine",
          "route": "PO/IM",
          "indication": "Psychiatric symptoms (agitation, psychosis); alternative to quetiapine",
          "dosing": {
            "doseOptions": [
              {
                "text": "2.5-5 mg",
                "orderSentence": "Olanzapine 2.5-5 mg PO/IM"
              }
            ],
            "route": "PO/IM",
            "instructions": "2.5-5 mg :: PO/IM :: as needed",
            "orderSentence": "Olanzapine 2.5-5 mg PO/IM"
          },
          "contraindications": "Avoid high doses (may lower seizure threshold)",
          "monitoring": "Sedation, metabolic effects",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Melatonin",
          "route": "PO",
          "indication": "Insomnia/sleep-wake disruption; common in anti-LGI1, NMDAR",
          "dosing": {
            "doseOptions": [
              {
                "text": "3-6 mg",
                "orderSentence": "Melatonin 3-6 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "3-6 mg :: PO :: qhs",
            "orderSentence": "Melatonin 3-6 mg PO"
          },
          "contraindications": "-",
          "monitoring": "-",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trazodone",
          "route": "PO",
          "indication": "Insomnia/sleep-wake disruption; alternative to melatonin",
          "dosing": {
            "doseOptions": [
              {
                "text": "25-50 mg",
                "orderSentence": "Trazodone 25-50 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "25-50 mg :: PO :: qhs",
            "orderSentence": "Trazodone 25-50 mg PO"
          },
          "contraindications": "Avoid benzodiazepines long-term",
          "monitoring": "-",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Labetalol",
          "route": "IV/PO",
          "indication": "Autonomic instability — hypertension in NMDAR encephalitis",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per hypertension protocol",
                "orderSentence": "Labetalol Per hypertension protocol IV/PO"
              }
            ],
            "route": "IV/PO",
            "instructions": "Per hypertension protocol :: IV/PO :: as needed",
            "orderSentence": "Labetalol Per hypertension protocol IV/PO"
          },
          "contraindications": "Avoid sympathomimetics",
          "monitoring": "ICU monitoring; central autonomic instability can be life-threatening; mechanical ventilation may be needed",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Atropine",
          "route": "IV",
          "indication": "Autonomic instability — bradycardia in NMDAR encephalitis",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per ACLS protocol",
                "orderSentence": "Atropine Per ACLS protocol IV"
              }
            ],
            "route": "IV",
            "instructions": "Per ACLS protocol :: IV :: as needed",
            "orderSentence": "Atropine Per ACLS protocol IV"
          },
          "contraindications": "-",
          "monitoring": "ICU monitoring; heart rate, rhythm",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Lorazepam",
          "route": "IV/PO",
          "indication": "Dystonia/dyskinesias in NMDAR encephalitis; orofacial dyskinesias and dystonic posturing",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5-2 mg",
                "orderSentence": "Lorazepam 0.5-2 mg IV/PO"
              }
            ],
            "route": "IV/PO",
            "instructions": "0.5-2 mg :: IV/PO :: as needed",
            "orderSentence": "Lorazepam 0.5-2 mg IV/PO"
          },
          "contraindications": "-",
          "monitoring": "Sedation; refractory cases may require ICU sedation",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Midazolam",
          "route": "IV",
          "indication": "Dystonia/dyskinesias in NMDAR encephalitis; alternative to lorazepam",
          "dosing": {
            "doseOptions": [
              {
                "text": "1-2 mg",
                "orderSentence": "Midazolam 1-2 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "1-2 mg :: IV :: as needed",
            "orderSentence": "Midazolam 1-2 mg IV"
          },
          "contraindications": "-",
          "monitoring": "Sedation, respiratory status",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Propofol",
          "route": "IV",
          "indication": "Severe refractory dystonia/dyskinesias in NMDAR encephalitis",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per ICU sedation protocol",
                "orderSentence": "Propofol Per ICU sedation protocol IV"
              }
            ],
            "route": "IV",
            "instructions": "Per ICU sedation protocol :: IV :: continuous infusion",
            "orderSentence": "Propofol Per ICU sedation protocol IV"
          },
          "contraindications": "-",
          "monitoring": "ICU sedation monitoring; propofol infusion syndrome risk",
          "ED": "-",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "STAT"
        }
      ]
    },
    "Other Recommendations": {
      "— Referrals": [
        {
          "rationale": "Specialized management of autoimmune encephalitis; immunotherapy selection and monitoring; long-term relapse prevention"
        },
        {
          "rationale": "All paraneoplastic cases — tumor staging, treatment planning; gynecologic oncology for teratoma"
        },
        {
          "rationale": "Refractory seizures, continuous EEG interpretation, ASM optimization"
        },
        {
          "rationale": "Psychiatric manifestations (especially NMDAR encephalitis — frequently misdiagnosed as primary psychiatric illness); capacity evaluation"
        },
        {
          "rationale": "Baseline and follow-up cognitive testing to document treatment response"
        },
        {
          "rationale": "Cognitive rehabilitation, motor recovery, speech/swallowing if affected"
        },
        {
          "rationale": "Insurance navigation (IVIG/rituximab are expensive — prior authorization), disability applications, caregiver support"
        }
      ]
    }
  }
}